PureTech Competitors
| PRTC Stock | USD 16.64 -0.22 -1.30% |
Pair Correlation for PureTech Health and Neumora Therapeutics Snapshot
Good diversification
The correlation between PRTC and NMRA is -0.09, which Macroaxis classifies as Good diversification for the selected horizon. Used correctly, the chart helps investors judge whether adding the second position genuinely diversifies the first.
Moving together with PureTech Stock
Moving against PureTech Stock
The degree to which PureTech Health's exhibits mean reversion depends on how efficiently the market prices new information. In highly covered equities, the mean reversion window tends to be shorter.
PureTech Health Competition Correlation Matrix
Correlation analysis between PureTech Health PLC and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between PureTech Stock performing well and PureTech Health Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze PureTech Health's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AUTL | 3.56 | 0.03 | 0.00 | -0.03 | 0.00 | 7.53 | 29.10 | |||
| NGNE | 3.94 | 0.21 | 0.05 | 0.32 | 3.98 | 8.73 | 31.07 | |||
| SLDB | 3.79 | 0.58 | 0.14 | 0.36 | 3.70 | 12.50 | 25.94 | |||
| QSI | 3.70 | -0.41 | 0.00 | -0.19 | 0.00 | 8.14 | 21.72 | |||
| LCTX | 3.04 | 0.03 | 0.00 | -0.01 | 0.00 | 4.65 | 21.47 | |||
| BNTC | 2.99 | -0.06 | 0.00 | -0.11 | 0.00 | 5.86 | 15.86 | |||
| ADCT | 3.28 | 0.53 | 0.14 | 0.29 | 3.36 | 8.03 | 24.46 | |||
| ALMS | 5.32 | 1.85 | 0.44 | 0.65 | 3.50 | 9.22 | 103.99 | |||
| RCKT | 3.22 | 0.57 | 0.16 | 0.77 | 3.10 | 9.29 | 22.29 | |||
| NMRA | 4.12 | 0.70 | 0.17 | 0.55 | 3.56 | 10.98 | 34.13 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in PureTech Health PLC financial statement analysis. It represents the amount of money remaining after all of PureTech Health PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare PureTech Health PLC and related stocks such as Autolus Therapeutics, Neurogene, and Solid Biosciences LLC Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUTL | -31.1 M | -31.1 M | -31.1 M | -31.1 M | -31.1 M | -7.5 M | -12.6 M | -19.7 M | -31.1 M | -123.8 M | -142.1 M | -142.1 M | -148.8 M | -208.4 M | -220.7 M | -198.6 M | -188.7 M |
| NGNE | -10.5 M | -10.5 M | -7.7 M | -8.7 M | -23.8 M | -21.9 M | -37 M | -50.2 M | -31.6 M | -69.4 M | -33.3 M | -50.5 M | -55.2 M | -36.3 M | -75.1 M | -67.6 M | -64.2 M |
| SLDB | -6.4 M | -6.4 M | -6.4 M | -6.4 M | -6.4 M | -6.4 M | -21.5 M | -52.1 M | -74.8 M | -117.2 M | -88.3 M | -72.2 M | -86 M | -96 M | -124.7 M | -112.2 M | -117.8 M |
| QSI | -35.8 M | -35.8 M | -35.8 M | -35.8 M | -35.8 M | -35.8 M | -35.8 M | -35.8 M | -35.8 M | -35.8 M | -36.6 M | -95 M | -132.4 M | -96 M | -101 M | -101.3 M | -106.4 M |
| LCTX | -700 K | -16.5 M | -21.4 M | -43.9 M | -36.4 M | -47 M | 33.6 M | -20 M | -46 M | -11.7 M | -20.6 M | -43 M | -26.3 M | -21.5 M | -18.6 M | -63.5 M | -60.4 M |
| BNTC | -6.4 M | -6.4 M | -6.4 M | -10.8 M | -8.8 M | -18.5 M | -4.4 M | -8.6 M | 2.9 M | -8.3 M | -13.9 M | -18.2 M | -19.6 M | -21.8 M | -37.9 M | -34.1 M | -32.4 M |
| ADCT | -89.9 M | -89.9 M | -89.9 M | -89.9 M | -89.9 M | -89.9 M | -89.9 M | -89.9 M | -123.1 M | -116.5 M | -246.3 M | -230 M | -157.1 M | -240.1 M | -157.8 M | -142.6 M | -149.8 M |
| ALMS | -111.9 M | -111.9 M | -111.9 M | -111.9 M | -111.9 M | -111.9 M | -111.9 M | -111.9 M | -111.9 M | -111.9 M | -111.9 M | -111.9 M | -111.9 M | -155 M | -294.2 M | -264.8 M | -278.1 M |
| RCKT | -6.1 M | -6.1 M | -6.1 M | -7.6 M | -9.5 M | -68 M | -42.9 M | -29.5 M | -74.5 M | -83.2 M | -146.7 M | -169.1 M | -221.9 M | -245.6 M | -258.7 M | -223.1 M | -212 M |
| NMRA | -99.3 M | -99.3 M | -99.3 M | -99.3 M | -99.3 M | -99.3 M | -99.3 M | -99.3 M | -99.3 M | -99.3 M | -99.3 M | -237.3 M | -130.9 M | -235.9 M | -243.8 M | -219.4 M | -230.4 M |
PureTech Health Competitive Analysis
Placing PureTech Health next to Autolus Therapeutics, Neurogene, and Solid Biosciences puts raw numbers into competitive context. A 402.4 M valuation paired with 4.8 M in revenue sets the baseline. Profitability stands at a 792.96% net margin with return on equity reaching 9.44%. On equity returns, PureTech Health earns 9.44% compared to -60.56% at Autolus Therapeutics. PureTech Health pulls in 4.8 M in revenue while the other reports 925,000. PureTech Health is dwarfed by Solid Biosciences on market cap at 569.5 M versus 402.4 M.| Better Than Average | Worse Than Peers | View Performance Chart |
Peer Performance Charts
How to Analyze PureTech Health Against Peers
PureTech Health's peer analysis compares PureTech Health with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether PureTech Health trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where PureTech Health leads or lags and what catalysts could close or widen the gap.